Polatuzumab, bendamustin und rituximab

Phase 2Monoclonal antibody

Polatuzumab, bendamustin und rituximab is one of 54 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell LymphomaActive, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

189 competitors in Mantle Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

82 2

Venclexta

AbbVie

Phase 3

18 3

Imbruvica

PPharmacyclics LLC.

Phase 3

37 4

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

26 5

Jaypirca

Eli Lilly

Phase 3

8 6

Treanda

AAzurity Pharmaceuticals

Phase 3

17 7

Brukinsa

BBeOne Medicines

Phase 3

16 8

Oncovin

EEastern Cooperative Oncology Group

Phase 3

11 9

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

6 10

Beqalzi

BBeOne Medicines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Mantle Cell Lymphoma

NCT05868395

Clinical

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Recruiting·MMedical University of Vienna·Phase 2·NCT05868395·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Polatuzumab, bendamustin und rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polatuzumab, bendamustin und rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polatuzumab, bendamustin und rituximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MMedical University of Vienna

Polatuzumab, bendamustin und rituximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News